Skip to Content
MilliporeSigma
All Photos(1)

Documents

1437009

USP

Methylprednisolone hemisuccinate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

11β,17,21-Trihydroxy-6α-methylpregna-1,4-diene-3,20-dione 21-succinate, Methylprednisolone hydrogen succinate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C26H34O8
CAS Number:
2921-57-5
Molecular Weight:
474.54
UNSPSC Code:
41116107
NACRES:
NA.24

API family

methylprednisolone

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C26H34O8.Na/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24;/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31);/q;+1/p-1/t14-,16-,17-,19-,23+,24-,25-,26-;/m0./s1

InChI key

FQISKWAFAHGMGT-SGJOWKDISA-M

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Methylprednisolone hemisuccinate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1435003

Methylprednisolone, United States Pharmacopeia (USP) Reference Standard

M1750000

Methylprednisolone, European Pharmacopoeia (EP) Reference Standard

M1755200

Methylprednisolone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard

M1755220

Methylprednisolone hydrogen succinate for performance test, European Pharmacopoeia (EP) Reference Standard

M1755000

Methylprednisolone acetate, European Pharmacopoeia (EP) Reference Standard

1436006

Methylprednisolone acetate, United States Pharmacopeia (USP) Reference Standard

PHR1718

Methylprednisolone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1717

Methylprednisolone, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001759

Methylprednisolone hydrogen succinate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001736

Methylprednisolone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001760

Methylprednisolone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001799

Methylprednisolone for system suitability A, European Pharmacopoeia (EP) Reference Standard

1435036

Methylprednisolone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1435014

Methylprednisolone Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP248

Methylprednisolone, British Pharmacopoeia (BP) Reference Standard

BP249

Methylprednisolone acetate, British Pharmacopoeia (BP) Reference Standard

BP572

Deltamedrane, British Pharmacopoeia (BP) Reference Standard

1437042

Methyl Prednisolone Hemisuccinate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1437020

Methylprednisolone Hemisuccinate Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR3043

Methylprednisolone Related Compound C, pharmaceutical secondary standard, certified reference material

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Repr. 1B - STOT RE 2

Storage Class

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Dexamethasone ≥98% (HPLC), powder

Sigma-Aldrich

D1756

Dexamethasone

S Pescina et al.
International journal of pharmaceutics, 451(1-2), 12-17 (2013-05-01)
Trans-scleral iontophoresis, i.e. the application of small electric current to enhance drug transport across sclera is an option for non-invasive delivery of corticosteroids to the posterior segment of the eye. In this paper, in vitro trans-scleral iontophoresis of methylprednisolone hemisuccinate
Hirofumi Oyama et al.
Neurologia medico-chirurgica, 52(10), 769-773 (2012-10-26)
A 51-year-old female with a history of rheumatoid arthritis rapidly developed anterior neck pain and paresis in the left upper and lower extremities and right lower extremity, sensory disturbance in the left upper and lower extremities, and bladder and rectal
M Sayın et al.
Neurologia i neurochirurgia polska, 47(4), 345-351 (2013-08-30)
Free radical production after spinal cord injury (SCI) plays an important role in secondary damage. The aim of this study was to investigate neuroprotective effects of the powerful antioxidant alpha-lipoic acid (ALA) in a spinal cord clip compression injury model.
Christos Krogias et al.
JAMA neurology, 70(8), 1056-1059 (2013-06-20)
A patient with a Caspr2 autoantibodies-associated syndrome had an unusual clinical triad and an excellent response to B-cell-anergizing therapy using the humanized monoclonal antibody tocilizumab directed against the interleukin 6 (IL-6) receptor. A 55-year-old man had an atypical clinical triad
Ming Jiang et al.
Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 27(5), 363-365 (2014-03-22)
To study the efficacy of early, enough methylprednisone combined with immunoglobulin in treatments of severe hand-foot-mouth disease. 568 patients of severe hand-foot-mouth disease involved were randomized into group A and group B. Patients of both groups all accepted symptomatic treatment
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service